Breaking News
Get 45% Off 0
📅 Plan for Wealth: Key market movers that could make (or break) your week
See Calendar
Close

Novo Nordisk A/S (NVO)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Novo Nordisk ADR's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
54.29 +0.01    +0.02%
- Closed. Currency in USD
After Hours
54.28
-0.02
-0.04%
- Real-time Data
Type:  Equity
Market:  United States
  • Volume: 20,325,578
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 52.72 - 54.30
Novo Nordisk ADR 54.29 +0.01 +0.02%

NVO Recent Sentiments

 
This page features our user's sentiments regarding the Novo Nordisk A/S share. They are displayed on both charts of different time periods and in a detailed table.
BearishBullish
Start Date Username Call Open Rate End Date Chg. %
Sep 09, 2025 FCO JAVIER CASTRO...   53.86 +0.80%
Sep 09, 2025 Javier Reinoso   53.94 +0.65%
Sep 09, 2025 Manuel Alvarez   53.91 Sep 09, 2025 @ 53.91 0.00%
Sep 09, 2025 Luca Moretto   54.01 +0.52%
Sep 09, 2025 David Vanhoucke   53.98 +0.57%
Sep 09, 2025 Adrian Gavril   53.93 +0.67%
Sep 09, 2025 Tamás Tôth   53.75 +1.00%
Sep 09, 2025 Victor LaRock   53.82 -0.87%
Sep 09, 2025 stefano ghione   53.74 +1.02%
Sep 09, 2025 Fabio Mazzoleni   53.30 +1.86%
Sep 09, 2025 George Arslanoglou   53.27 +1.91%
Sep 09, 2025 Brandon Siko   53.35 +1.76%
Sep 09, 2025 Trading Desk   53.11 -2.22%
Sep 09, 2025 Marco Reale   53.11 +2.22%
Sep 09, 2025 feridun gayret   54.12 +0.31%
Sep 09, 2025 Javier Rodriguez   53.30 +1.86%
Sep 09, 2025 pru coex   53.00 +2.43%
Sep 09, 2025 拓実 佐々木   54.32 -0.06%
Sep 08, 2025 Paolo Bussi   54.39 -0.18%
Sep 08, 2025 tony scotton   54.29 0.00%
Sep 08, 2025 marcin dk   54.32 -0.06%
Sep 08, 2025 David Kirkwood   54.30 -0.02%
Sep 08, 2025 Эмин Гадиров   54.16 +0.24%
Sep 08, 2025 David DG   54.58 -0.53%
Sep 08, 2025 Hasan Basri CETINKAYA   54.65 -0.66%
Sep 08, 2025 Michael Bloching   54.73 +0.80%
Sep 08, 2025 Rodrigo Lechuga...   54.65 -0.66%
Sep 08, 2025 REGINALDO DE LIMA   54.35 -0.11%
Sep 08, 2025 Samuel Alvarez   54.23 +0.11%
Sep 08, 2025 拓実 佐々木   55.19 Sep 08, 2025 @ 54.85 -0.62%
Sep 08, 2025 francisco javier...   55.00 Sep 08, 2025 @ 54.85 -0.27%
Sep 08, 2025 Göran Samuelsson   55.37 -1.95%
Sep 08, 2025 Rafael Lopez   55.19 Sep 08, 2025 @ 54.85 -0.62%
Sep 08, 2025 MINKO JONKOV   54.15 +0.26%
Sep 08, 2025 Gregorio piñero   55.00 Sep 08, 2025 @ 54.85 -0.27%
Sep 08, 2025 נללה אברמוב   55.19 Sep 08, 2025 @ 54.85 -0.62%
Sep 08, 2025 Piero Rebosio   55.00 -1.29%
Sep 08, 2025 Dominik Voss   55.19 Sep 08, 2025 @ 54.85 -0.62%
Sep 05, 2025 eduardo adan gomez   55.15 -1.56%
Sep 05, 2025 Simone Gazzurelli   55.14 Sep 08, 2025 @ 54.85 +0.53%
Sep 05, 2025 Jose Miguel Fonseca   55.17 -1.60%
Sep 05, 2025 Agustin R   55.02 -1.33%
Sep 05, 2025 XY Z   55.01 +1.31%
Sep 05, 2025 Shiro Barkl   54.95 -1.20%
Sep 05, 2025 MICHELE BEDA   55.16 -1.58%
Sep 05, 2025 Paul stokker   55.24 -1.72%
Sep 05, 2025 Laufar Laufar   54.90 -1.11%
Sep 05, 2025 Matteo Quarenghi   55.04 Sep 08, 2025 @ 54.85 -0.35%
Sep 05, 2025 Mariano Fernandez   55.50 -2.18%
Sep 05, 2025 Bahtiyar Anarbaev   56.18 Sep 08, 2025 @ 54.85 -2.37%
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

NVO Comments

Write your thoughts about Novo Nordisk A/S
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email